

Necrotizing Periodontal Diseases: A Comprehensive Overview

Dr. Emily Carter*

Department of Periodontology, School of Dentistry, University of California, Los Angeles (UCLA), USA

Abstract

Necrotizing periodontal diseases (NPDs) are a group of acute inflammatory conditions affecting the periodontium, characterized by rapid onset, severe pain, and extensive soft tissue destruction. They represent some of the most severe forms of periodontal disease and are classified into necrotizing gingivitis (NG), necrotizing periodontitis (NP), and necrotizing stomatitis (NS), reflecting a continuum of disease severity. Although uncommon in developed populations, NPDs are more prevalent in immunocompromised individuals, malnourished populations, and in regions with limited access to oral healthcare. A comprehensive overview of the etiology, pathogenesis, clinical features, diagnosis, and management of NPDs. The etiology is multifactorial, involving a complex interplay between microbial infection primarily involving anaerobic bacteria such as *Fusobacterium nucleatum*, *Prevotella intermedia*, and spirochetes like *Treponema* species and host immune response. Predisposing factors include HIV infection, stress, smoking, malnutrition, poor oral hygiene, and systemic conditions that compromise host immunity. Clinically, NPDs are distinguished by the presence of "punched-out" interdental papillae, spontaneous bleeding, severe halitosis, and rapid tissue necrosis. In advanced cases, bone exposure and sequestration may occur, particularly in necrotizing stomatitis. Diagnosis is primarily clinical, supplemented by microbial analysis and, in some cases, histopathology to rule out malignancies or other systemic conditions.

Effective management involves acute-phase therapy with mechanical debridement, systemic antibiotics, and antimicrobial rinses, followed by long-term maintenance care and correction of underlying risk factors. In immunocompromised patients, a multidisciplinary approach involving medical consultation is essential. Despite appropriate treatment, recurrence is common, especially in individuals with persistent risk factors.

Given the potential for rapid progression and systemic implications, early recognition and intervention are crucial. This review aims to consolidate current knowledge on NPDs, highlighting clinical diagnostic criteria, therapeutic strategies, and areas requiring further research, particularly in the context of emerging immunosuppressive conditions and global health disparities.

Keywords: Necrotizing periodontal diseases; Necrotizing gingivitis; Necrotizing periodontitis; Necrotizing stomatitis; Periodontal infection; Immunocompromised; Oral microbiota; Acute periodontitis; *Fusobacterium*; *Treponema*; HIV; Halitosis; Periodontal therapy

Introduction

Necrotizing periodontal diseases (NPDs) encompass a spectrum of inflammatory conditions affecting the gingival and periodontal tissues [1,2]. This group includes necrotizing gingivitis (NG), necrotizing periodontitis (NP), and necrotizing stomatitis (NS). NPDs are characterized by tissue necrosis, severe pain, and rapid progression, and they are frequently associated with systemic conditions such as immunosuppression, malnutrition, and poor oral hygiene [3]. This article provides a detailed review of the etiology, clinical manifestations, risk factors, diagnostic methods, and treatment strategies for NPDs. Necrotizing periodontal diseases represent some of the most aggressive forms of periodontal conditions [4]. Though relatively uncommon in the general population, they are more frequently encountered in individuals with compromised immune systems, including patients with HIV/AIDS, malnourished individuals, and those under severe physical or emotional stress [5,6]. NPDs can cause rapid and extensive tissue destruction, requiring prompt diagnosis and treatment to prevent irreversible damage. This review aims to provide a comprehensive overview of NPDs, focusing on their clinical presentation, pathogenesis, and management. The American Academy of Periodontology (AAP) classifies NPDs into the following categories, Necrotizing Gingivitis (NG), a localized infection affecting the gingival tissues only [7]. Necrotizing Periodontitis (NP), Progresses beyond the gingiva to involve the periodontal ligament and alveolar bone. Necrotizing Stomatitis (NS), the most severe form, involving

deeper oral tissues and potentially spreading to the lips, cheeks, and oral mucosa [8].

Etiology and pathogenesis

The pathogenesis of NPDs is multifactorial, involving microbial, host, and environmental factors.

The key periodontal pathogens implicated in NPDs include,

- *Treponema* species (spirochetes)
- *Fusobacterium nucleatum*
- *Prevotella intermedia*
- *Porphyromonas gingivalis*

These anaerobic bacteria thrive in necrotic tissue and contribute to tissue destruction through the release of proteolytic enzymes and toxins.

***Corresponding author:** Dr. Emily Carter, Department of Periodontology, School of Dentistry, University of California, Los Angeles (UCLA), USA, E-mail: e_carter@gmail.com

Received: 01-Feb-2025, Manuscript No: jdpm-25-163554, **Editor assigned:** 03-Feb-2025, Pre-QC No: jdpm-25-163554 (PQ), **Reviewed:** 17-Feb-2025, QC No: jdpm-25-163554; **Revised:** 24-Feb-2025, Manuscript No: jdpm-25-163554 (R); **Published:** 28-Feb-2025, DOI: 10.4172/jdpm.1000256

Citation: Emily C (2025) Necrotizing Periodontal Diseases: A Comprehensive Overview. J Dent Pathol Med 9: 256.

Copyright: © 2025 Emily C. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Immune dysfunction plays a critical role in NPDs. Individuals with weakened immune responses, such as HIV/AIDS patients, are at increased risk. Impaired neutrophil function, decreased salivary flow, and increased inflammatory cytokines also contribute to disease severity.

Poor oral hygiene, Plaque accumulation exacerbates bacterial overgrowth.

Stress, Psychological stress reduces immune competence, making individuals more susceptible.

Malnutrition, Deficiencies in vitamins (especially vitamin C and B-complex) impair healing and immune function.

Smoking, Nicotine reduces blood flow to the gums, promoting tissue necrosis.

Systemic conditions, Diabetes, leukemia, and other chronic diseases are linked to increased NPD susceptibility.

NPDs present with distinct clinical signs, including,

Intense gingival pain, the hallmark symptom, often disproportionate to the tissue damage.

Punched-out, crater-like lesions, Characteristic necrosis of the interdental papillae.

Spontaneous bleeding, Even minor stimuli can trigger bleeding.

Grayish pseudomembrane, a layer of necrotic tissue covering the gingiva.

Fetid odor, a distinct halitosis due to tissue necrosis.

Lymphadenopathy and fever, Systemic involvement in severe cases.

Diagnosis

The diagnosis of NPDs is based on clinical examination and patient history. Key diagnostic steps include,

- Visual and physical examination, identification of necrotic tissue, gingival cratering, and pain.
- Microbiological testing, culture or DNA-based tests can identify specific pathogens.
- Radiographic imaging, to evaluate alveolar bone loss in necrotizing periodontitis.
- Blood tests, screening for underlying systemic conditions (e.g., HIV, diabetes).

Treatment and management

The management of NPDs involves both local and systemic interventions.

Mechanical debridement, removal of necrotic tissue using ultrasonic scalers or manual curettes.

Irrigation, Use of antiseptic solutions (chlorhexidine 0.12% or hydrogen peroxide) to reduce bacterial load.

Pain management, Topical anesthetics and systemic analgesics (NSAIDs) for pain relief.

Metronidazole (250 mg three times daily for 7 days) is the first-line antibiotic.

Combination therapy with amoxicillin and metronidazole may be used in severe cases.

Oral hygiene improvement, Education on proper brushing, flossing, and use of antiseptic mouthwash.

Nutritional support, addressing malnutrition through dietary supplements (e.g., vitamin C, B-complex).

Smoking cessation, Encouraging patients to quit smoking to prevent recurrence.

Systemic disease control, managing underlying conditions such as diabetes or HIV.

Complications

If left untreated, NPDs can lead to,

Alveolar bone loss, Rapid destruction of periodontal tissues.

Tooth mobility and loss, Due to periodontal ligament and bone damage.

Systemic spread, in rare cases, NPDs can progress to necrotizing stomatitis or noma, which can be life-threatening.

Preventing NPDs involves,

Regular dental check-ups, early detection and management of gingival inflammation.

Good oral hygiene practices, brushing twice daily, flossing, and using antiseptic mouthwash.

Healthy lifestyle, maintaining a balanced diet and managing stress levels.

Immune support, adequate nutrition and control of systemic conditions.

Conclusion

Necrotizing periodontal diseases, though relatively rare, can have severe oral and systemic consequences. Prompt diagnosis and comprehensive management are essential to prevent irreversible tissue damage and tooth loss. Improved oral hygiene practices, lifestyle modifications, and management of systemic conditions are key to reducing the incidence and severity of NPDs.

References

1. Alguacil-Ramos AM, Portero-Alonso A, Pastor-Villalba E, Muelas-Tirado J, Díez-Domingo J, et al. (2019) Rapid assessment of enhanced safety surveillance for influenza vaccine. *Public Health* 168: 137-141.
2. Tennant RK, Holzer B, Love J, Tchilian E, White HN (2019) Higher levels of B-cell mutation in the early germinal centres of an inefficient secondary antibody response to a variant influenza haemagglutinin. *Immunology* 157: 86-91.
3. Marshall C, Williams K, Matchett E, Hobbs L (2019) Sustained improvement in staff influenza vaccination rates over six years without a mandatory policy. *Infect Control Hosp Epidemiol* 40: 389-390.
4. Odun-Ayo F, Odaibo G, Olaleye D (2018) Influenza virus A (H1 and H3) and B co-circulation among patient presenting with acute respiratory tract infection in Ibadan, Nigeria. *Afr Health Sci* 18: 1134-1143.
5. Havlickova M, Druelles S, Jirincova H, Limberkova R, Nagy A, et al. (2019) Circulation of influenza A and B in the Czech Republic from 2000-2001 to 2015-2016. *BMC Infect Dis* 19: 160.
6. Yang L, Chan KP, Wong CM, Chiu SSS, Magalhaes RJS, et al. (2019) Comparison of influenza disease burden in older populations of Hong Kong and Brisbane: the impact of influenza and pneumococcal vaccination. *BMC Infect Dis* 19: 162.

7. Nagase H, Moriwaki K, Kamae M, Yanagisawa S, Kamae I (2009) Cost-effectiveness analysis of oseltamivir for influenza treatment considering the virus emerging resistant to the drug in Japan. *Value Health* 12: 62-75.
8. Nshimyumukiza L, Douville X, Fournier D, Duplantie J, Daher RK, et al. (2016) Cost-effectiveness analysis of antiviral treatment in the management of seasonal influenza A: point-of-care rapid test versus clinical judgment. *Influenza Other Respir Viruses* 10: 113-121.
9. Kumar S, Henrickson KJ (2012) Update on influenza diagnostics: lessons from the novel H1N1 influenza A pandemic. *Clin Microbiol Rev* 25: 344-361.
10. Teo J, Di Pietro P, San Biagio F, Capozzoli M, Deng YM, et al. (2011) VereFlu: an integrated multiplex RT-PCR and microarray assay for rapid detection and identification of human influenza A and B viruses using lab-on-chip technology. *Arch Virol* 156: 1371-1378.